Pomerantz LLP has filed a class action lawsuit against Phreesia, Inc. concerning potential securities fraud or unlawful business practices. Investors who purchased or acquired Phreesia securities during the class period have until July 13, 2026 to seek appointment as lead plaintiff. The lawsuit follows Phreesia's March 30, 2026 announcement of significantly reduced revenue growth projections for fiscal year 2027, citing worsening visibility and weaker pharmaceutical marketing commitments. On this news, Phreesia's stock price fell $3.03 per share, or 26.56%, to close at $8.38 per share on March 31, 2026.
Phreesia IncPhreesia announced reduced revenue growth projections, causing a 26.56% stock drop, and faces a securities class action lawsuit.